Gemcitabine, when combined with several anti-cancer agents showed the similar effect as EBR in pancreatic cells, including BH3 mimetic ABT-199, Chk1 inhibitors, or nabpaclitaxel (Bennett et al., 2012; Zhou et al., 2018; Passacantilli et al., 2018). The gene discussed is CHEK1; the disease is cancer.